UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042300
Receipt number R000048257
Scientific Title Online survey and patient advisory board for chronic kidney disease patients in Japan - A study of the experiences and perceptions of patients with chronic kidney disease using mixed methods research -
Date of disclosure of the study information 2020/10/30
Last modified on 2020/10/30 17:59:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Online survey and patient advisory board for chronic kidney disease patients in Japan
- A study of the experiences and perceptions of patients with chronic kidney disease using mixed methods research -

Acronym

A study of the experiences and perceptions of patients with chronic kidney disease using mixed methods research

Scientific Title

Online survey and patient advisory board for chronic kidney disease patients in Japan
- A study of the experiences and perceptions of patients with chronic kidney disease using mixed methods research -

Scientific Title:Acronym

A study of the experiences and perceptions of patients with chronic kidney disease using mixed methods research

Region

Japan


Condition

Condition

Chronic kidney disease

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate the experiences and perceptions of the disease and treatment of patients with chronic kidney disease (CKD) in order to understand patient needs and expectations for new treatments and clinical trials

Basic objectives2

Others

Basic objectives -Others

Not applicable

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

1) Information on patient background and CKD patients' experiences and perceptions of the disease and treatment from patient surveys
2) Information about CKD patients' experiences and perceptions of the disease and treatment from the Patient Advisory Board

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who meet all of the following criteria at the time of enrollment in this study will be eligible for this study
1) Patients aged 20 years or older
2) Patients with a diagnosis of CKD
3) Patients who can access the website and complete the survey
4) Patients willing to participate in the Patient Advisory Board to be held at a later date
5) Patients whose consent is obtained from the patient on the website prior to the start of this study

Key exclusion criteria

Patients who meet any of the exclusion criteria will not be enrolled in this study
1) Patients on maintenance dialysis (hemodialysis or peritoneal dialysis) or who planed those
2) Patients who have received or planned to receive a kidney transplant

Target sample size

300


Research contact person

Name of lead principal investigator

1st name Nobutaka
Middle name
Last name Yagi

Organization

Nippon Boehringer Ingelheim Co., Ltd.

Division name

Medicine Division

Zip code

141-6017

Address

2-1-1 Osaki, Shinagawa-ku, Tokyo, Japan

TEL

03-6417-2043

Email

nobutaka.yagi@boehringer-ingelheim.com


Public contact

Name of contact person

1st name Nobutaka
Middle name
Last name Yagi

Organization

Nippon Boehringer Ingelheim Co., Ltd.

Division name

Medicine Division

Zip code

141-6017

Address

2-1-1 Osaki, Shinagawa-ku, Tokyo, Japan

TEL

03-6417-2043

Homepage URL


Email

nobutaka.yagi@boehringer-ingelheim.com


Sponsor or person

Institute

Nippon Boehringer Ingelheim Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Nippon Boehringer Ingelheim Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Corporation Kyoso-kai AMC Nishi-Umeda Clinic Ethics Review Committee

Address

Maruit Nishi-Umeda Building 3F, 3-3-45 Umeda, Kita-ku, Osaka-shi, Osaka, Japan

Tel

06-4797-5660

Email

morikawa@amc-clinic.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 10 Month 30 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2020 Year 10 Month 15 Day

Date of IRB

2020 Year 10 Month 23 Day

Anticipated trial start date

2020 Year 10 Month 30 Day

Last follow-up date

2020 Year 11 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The study will collect data by web-based patient questionnaire and a patient advisory board.
Patient questionnaires will collect information on experiences and perceptions of CKD diagnosis and treatment.
A patient advisory board will collect detailed information on patient burden and future treatment needs and expectations.


Management information

Registered date

2020 Year 10 Month 30 Day

Last modified on

2020 Year 10 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048257


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name